We use antiplatelets in stroke prevention day in and day out, but are we confident enough about their expected effects on the human body? On many occasions, they do not produce the best results as antithrombotic measures, and they also cause unexpected bleeding manifestations. Can we take steps to ensure its maximum effectivity and avoid catastrophe? There is interindividual variability in the pharmacodynamic response to antiplatelet medications.